The MHRA also advises that patients who are carriers of HBV who require treatment with BCR-ABL tyrosine kinase inhibitors should be closely monitored for signs and symptoms of active HBV infection throughout treatment and for several months after stopping.
The manufacturers have also sent a letter to healthcare professionals about these recommendations.